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 Abstract   
Objectives: Endometrioid and clear cell ovarian adenocarcinomas are suspected to derive from ectopic endome-
trial foci. The aim of the study was to determine PTEN and MMP-2 immunoexpression in endometrial ovarian cysts, 
endometrioid and clear cell ovarian carcinomas and to assess the relationship between the abovementioned values 
and clinical data of patients in order to find the marker of increased risk of malignant proliferation based on ovarian 
endometriotic lesions. Detailed analysis of the collected data was conducted to investigate the correlation between 
immunohistochemical expression of the examined antigens, histopathological diagnosis and clinical condition of 
patients.
Material and methods: 20 endometrial adenocarcinomas, 21 clear cell ovarian cancers and 26 endometrial cysts 
were included in the study. The control group consisted of 29 specimens of physiological endometrium: 16 samples 
of the proliferative phase and 13 samples of the secretory phase.
Protein expression of PTEN and MMP-2 was evaluated by immunohistochemistry. Protein immunoexpression in the 
collected specimens was estimated with the use of light microscope and MultiScan software. Immunoreactivity of 
the PTEN antigen was assessed by the quantitative method, whereas MMP-2 immunoexpression was evaluated 
by the semi-quantitative method. 
Two-sided tests were used for statistical inference. Generalized linear models were used to compare the studied 
groups. Error distributions were selected using the Akaike criterion (AIC). Statistical analysis was conducted with 
the use of the R Statistical Package.
Results: MMP-2 immunoreactivity differed significantly between the study groups and controls (p<0.001). PTEN 
immunoexpression was the strongest in endometrial cysts (53.7 %), lower in clear cell cancers (50.2%) and the 
lowest in endometrioid adenocarcinomas (43.88%), but the differences were not statistically significant (p=0.17). 
PTEN reactivity in the group of endometrioid carcinomas was significantly higher (p=0.02), while MMP-2 expression 
had a falling tendency (p=0.076) in obese women.
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Introduction
Ovarian	cancer	has	the	worst	prognosis	of	all	gynecological	
malignancies	 [1].	 Although	 no	 cause-and-effect	 relationship	
between	 the	 presence	 of	 endometriosis	 and	 ovarian	 cancer	 has	
been	evidenced	thus	far,	numerous	data	suggesting	the	possibility	
of	cancer	proliferation	associated	with	ovarian	endometriosis	have	
been	reported	[2,	3].	Due	 to	similarity	of	ovarian	endometrioid	
and	 clear	 cell	 cancer	 morphology	 to	 that	 of	 uterine	 mucinous	
carcinomas,	 the	 former	 are	 suspected	 to	 derive	 from	 ectopic	
endometrial	foci.
PTEN	 protein	 is	 responsible	 for	 a	 multistage	 control	 of	
a	 cell	 cycle	 transformation	process	 [4,	 5].	Due	 to	 its	 structural	
homology	to	tensin,	PTEN	protein	reacts	with	the	cell	membrane	
proteins	 and	 elements	 of	 the	 extracellular	 matrix.	 Therefore,	
its	 involvement	in	malignant	 transformation	at	 the	stage	of	cell	
proliferation,	as	well	as	at	the	time	of	acquiring	the	ability	of	the	
cell	to	invade	tissues,	has	been	implied	[6].	Koul	et	al.,	observed	
a	correlation	between	the	activity	of	matrix	metalloproteinase-2	
(MMP-2)	and	PTEN	protein	activity	in	cancer	cell	lines	derived	
from	 the	outside	of	 reproductive	organs	 [6].	A	 similar	 analysis	
Conclusions: Increased MMP-2 expression in the successive groups may imply a rising invasive potential of the 
epithelial cells in endometrial cysts, endometrioid and clear cell adenocarcinomas. Strong immunoreactivity for 
PTEN in proliferative endometrium implies its role in the regulation of endometrial proliferation. PTEN activity may 
reduce MMP-2 expression in insulin resistant women suffering from endometrial ovarian cancer. Simultaneous eva-
luation of PTEN and MMP-2 immunoexpression in ectopic endometrial foci cannot be used to identify women with 
an increased risk of neoplastic transformation.
 Key words: endometriosis / endometrioid ovarian cancer / clear cell ovarian cancer / 
       / PTEN / MMP-2 /
 Streszczenie
Cele: Istnieje hipoteza o zwiększonym ryzyku powstawania ognisk raka endometrioidalnego i jasnokomórkowego 
jajnika na podłożu endometriozy jajnikowej. Celem pracy była analiza immunoreaktywności białka PTEN i metalo-
proteinazy-2 (MMP-2) w torbielach endometrialnych, raku endometrioidalnym i jasnokomórkowym jajnika w kontek-
ście poszukiwania markera zwiększonego ryzyka proliferacji nowotworowej na podłożu istniejących ognisk endome-
triozy jajnikowej a także ocena zależności pomiędzy immunoekspresją białka PTEN i metaloproteinazy-2 a stanem 
klinicznym kobiet z gruczolistością zewnętrzną oraz rakami endometrioidalnym i jasnokomórkowym jajnika. 
 Materiał i metody: grupy badane tworzył tkankowy materiał pooperacyjny pochodzący z torbieli endometrialnych 
(N1=26), raków endometrioidalnych jajnika (N2=20), raków jasnokomórkowych jajnika (N3=21). Grupę porównaw-
czą stanowiły preparaty niezmienionego endometrium (N4=29): fazy proliferacyjnej (n1=16) i wydzielniczej (n2=13).
Komórkową ekspresję białka PTEN oraz MMP-2 oceniano przy użyciu metod immunohistochemicznych. Immu-
noreaktywność badanych antygenów oceniano używając komputerowego systemu analizy obrazu. Immunoreak-
tywność antygenu PTEN oceniano metodą ilościową, natomiast antygenu MMP-przy użyciu metody półilościowej.
Wnioskowanie statystyczne przeprowadzono na poziomie 0,05 przy użyciu testów dwustronnych. Do porównania 
wartości średnich w badanych grupach zastosowano model regresji liniowej dla parametru PTEN oraz uogólniony 
model regresji linowej z rozkładem Gamma dla błędu losowego. Obliczeń statystycznych dokonano przy pomocy 
pakietu statystycznego R.
Wyniki: stwierdzono znamienne statystycznie różnice w  immunoekspresji MMP-2 pomiędzy grupami badanymi 
oraz porównawczą (p<0,001). Najsilniejsza immunoekspresja PTEN występowała w materiale z torbieli endome-
trialnych (53,7 %), kolejno słabsza była w materiale z raków jasnokomórkowych jajnika (50,2%), najmniej intensyw-
na wśród raków endometrioidalnych jajnika (43,88%), jednakże obserwacje nie były istotne statystycznie (p=0,17). 
W grupie chorych z rakiem endometrioidalnym jajnika immunoreaktywność PTEN była znamiennie wyższa u kobiet 
z nadwagą i otyłością (p=0,02), natomiast immunoekspresja MMP-2 w tej grupie wykazała tendencję spadkową 
(p=0,076).
Wnioski: Silniejsza immunoekspresja MMP-2 w kolejnych badanych grupach może wskazywać na wzrastający 
potencjał inwazyjny komórek nabłonkowych torbieli endometrialnych, raka endometrioidalnego i jasnokomórkowe-
go jajnika. Silna immunoreaktywność  białka PTEN w endometrium fazy proliferacyjnej  przemawia za jego udziałem 
w kontroli proliferacji nabłonka endometrium. 
Aktywność PTEN może hamować ekspresję MMP-2 wśród kobiet z insulinoopornością chorujących na raka en-
dometrioidalnego jajnika. Oznaczanie immunoreaktywności białka PTEN i MMP-2 w materiale tkankowym jaki wy-
korzystano w badaniu nie może być użyte jako marker zwiększonego ryzyka proliferacji nowotworowej na podłożu 
endometriozy jajnika.
 Słowa kluczowe: endometrioza / rak jajnika endometrioidalny /
     /  rak jajnika jasnokomórkowy / PTEN/ MMP-2 /
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has	not	been	performed	either	in	in	vitro	or	in	vivo	conditions	in	
tissue	samples	from	reproductive	organs.	Moreover,	no	data	on	
the	relationship	of	the	MMP-2	expression	and	activity	with	PTEN	
protein	activity	in	the	pathomechanism	of	ovarian	cancerogenesis	
have	been	published	to	date.
There	 are	 some	 reports	 on	 the	 prevalence	 of	 errors	 in	 the	
expression	 of	 genes	 responsible	 for	 the	 synthesis	 of	 enzymes	
decomposing	the	extracellular	matrix	(ECM)	among	patients	with	
endometriosis	 (7-10).	 So	 far,	 twenty	matrix	metalloproteinases	
have	been	described.	MMP-2	and	MMP-9	are	regarded	as	the	most	
important	 metalloproteinases	 for	 invasive	 processes	 observed	
in	 endometriosis	 and	 carcinogenesis	 [11-13].	 Coincidence	 of	
ovarian	cancer	and	endometriosis	remains	an	issue	[2,	14-21].
Similar	polymorphisms	and	mutations	in	the	suppressor	gene	
region	predominate	among	DNA	disorders	of	ectopic	endometrial	
and	cancer	cells.	One	of	the	most	frequent	genetic	dysfunctions	
is	 the	 impairment	 of	 PTEN/MMAC1	 (phosphatase	 and	 tensin	
homolog	 deleted	 from	 chromosome	 10/mutated	 in	 multiple	
advanced	cancers)	suppressor	gene	[7,	14,	15,	22-24].
The	aims	of	the	study	were	to	determine	immunoreactivity	
of	the	PTEN	protein	and	metalloproteinase-2	in	the	proliferative	
and	 secretory	 endometrium,	 endometrial	 cyst	 ependyma,	 and	
ovarian	 endometrioid	 and	 clear	 cell	 carcinoma;	 to	 analyze	 the	
relationship	between	immunoexpression	of	the	PTEN	protein	and	
matrix	MMP-2	and	the	clinical	state	of	the	studied	women	and	to	
verify	the	PTEN	protein	and	matrix	MMP-2	immunoreactivity	as	
markers	of	an	 increased	risk	for	cancer	proliferation	associated	
with	ovarian	endometriotic	lesions.	
Material and methods
Study material 
Tissue	 samples	were	gathered	during	 surgical	 treatment	of	
96	 patients	 hospitalized	 at	 various	 departments	 of	 the	 Polish	
Mother’s	 Health	 Centre	 Research	 Institute	 between	 1999	 and	
2009.	The	control	samples	were	collected	during	routine	curettage	
of	uteri	of	women	hospitalized	for	static	disorders	of	the	pelvic	
organs.	
The	following	study	groups	were	distinguished:	patients	with	
ovarian	 endometrial	 cysts	 (N1=26),	 with	 ovarian	 endometrioid	
adenocarcinoma	(N2=20)	and	with	ovarian	clear	cell	carcinoma	
(N
3
=21).	The	control	group	consisted	of	women	with	physiological	
endometrium	(N
4
=29)	in	the	proliferative	(n1=16)	and	secretory	
(n2=13)	phases.
Histopathological	 diagnoses	 were	 established	 at	 the	
Department	of	Pathomorphology	 in	accordance	with	 the	World	
Health	Organization	classification.	
Immunohistochemistry 
Tissue	 sections	 were	 embedded	 in	 paraffin	 according	 to	
standard	 procedures.	 Four-micrometer	 sections	 were	 cut	 and	
mounted	on	slides.	The	sections	were	deparaffinized	by	xylene	
and	rehydrated	in	graded	ethanol	baths.
In	 order	 to	 depict	 the	 needed	 antigens,	 the	 sections	 were	
incubated	 in	 a	 water	 bath	 at	 97°C	 for	 40	min	 with	 a	 0.001M	
versenate	 buffer	 (EDTA)	 of	 pH	 8.0	 for	 MMP-2	 and	 a	 Target	
Retrieval	Solution	buffer	at	pH	9.0	for	the	PTEN	protein.	After	
cooling,	 the	 sections	were	 rinsed	 in	 0.05M	TRIS	 buffer	 (Tris-
Buffered	Saline,	DAKO)	and	 incubated	 in	a	humidity	chamber	
at	 room	 temperature	 for	 60	 min	 with	 appropriately	 diluted	
antibodies:	 Monoclonal-Mouse	 Anti-Human	 PTEN	 Clone	
6H2.1	 (DAKO)	 1:100	 and	 Lyophilized	 Mouse	 Monoclonal	
Antibody	MMP-2	 (Novocastra)	 1:60.	After	 the	 incubation,	 the	
sections	 were	 rinsed	 twice	 in	 TRIS	 buffer	 and	 the	 two-stage	
visualization	system	DAKO	EnVision	was	used	 to	disclose	 the	
antigen-antibody	reaction.	The	first	stage	of	the	reaction	included	
30	 min	 incubation	 with	 a	 peroxidase-labeled	 polymer	 linked	
to	 secondary	 goat	 antibodies	 directed	 against	 the	 monoclonal	
antibodies	 used.	 The	 last	 stage	 of	 detection	 demonstrated	 an	
enzymatic	 reaction	 in	 which	 staining	 was	 elicited	 by	 using	
a	 peroxidase	 substrate,	 3,3’-diaminobenzidine	 (DAB).	 After	
receiving	a	color	immunohistochemical	reaction,	cellular	nuclei	
were	 stained	 with	 Meyer’s	 hematoxylin	 and	 dehydrated	 by	
increasing	concentrations	of	ethanol	and	passing	through	a	series	
of	 xylene.	 Finally,	 the	 specimens	 were	 mounted	 on	 sialinized	
slides	 and	 covered	with	Canadian	 balm.	 Positive	 and	 negative	
controls	were	provided.
Evaluation of immunoreactivity
Analysis	was	performed	without	 the	knowledge	of	clinical	
and	histopathological	parameters.
The	 PTEN	 antigen	 immunoreactivity	was	 evaluated	 using	
the	 image	 analysis	 computer	 system.	 A	 stained	 (dark	 brown)	
product	of	 immunohistochemical	 reaction	 inside	 the	nucleus	or	
cytoplasm	was	considered	a	positive	response.	
The	PTEN	antigen	immunoreactivity	was	established	using	
the	 quantitative	 method.	 The	 percentage	 value	 of	 positively	
stained	 cells	 per	 1000	 cells	 was	 calculated.	 The	 antigen	
immunoreactivity	index	was	expressed	as	percentages.
MMP-2	 antigen	 immunoreactivity	 was	 evaluated	 by	
observing	 10	 adjacent	 vision	 fields	 in	 the	 light	 microscope	 at	
200x	magnification.	The	first	field	was	 selected	 randomly.	The	
intracytoplasmic	presence	of	 the	stained	product	(slight	brown)	
of	immunohistochemical	reaction	signified	a	positive	response.
Due	 to	 the	 presence	 of	 the	 MMP-2	 antigen	 in	 the	 cell	
cytoplasm	 and	 the	 extracellular	 environment,	 the	 semi-
quantitative	method	was	 used	 to	 evaluate	 immunoreactivity	 of	
this	 antigen:	 0	 –	 no	 reaction;	 1	 –	mild	 reaction;	 2	 –	moderate	
reaction;	3	–	strong	reaction.
Two	 independent	 examiners	 performed	 the	 assessment	 in	
order	 to	 objectively	 verify	 immunoexpression	 of	 the	 studied	
antigens.				
Statistical analysis of the results 
Two-sided	 tests	 were	 used	 at	 a	 significance	 level	 of	 0.05	
to	analyze	 the	obtained	data.	A	 linear	 regression	model	 for	 the	
PTEN	parameter	and	a	generalized	linear	regression	model	with	
a	gamma	distribution	for	a	random	error	were	used	to	compare	
mean	values	of	 the	 studied	parameters.	The	model	was	chosen	
on	 the	 basis	 of	 the	 information	 criterion	Akaike	 (AIC).	 First,	
the	differences	between	the	groups	were	compared.	The	second	
stage	 of	 the	 analysis	 included	 an	 effect	 of	 other	 factors	 (age,	
BMI,	 hypothyroidism,	 etc.)	 on	 the	 parameters.	 Each	 group	
as	 well	 as	 the	 mean	 difference	 in	 all	 groups	 were	 compared.	
The	 interaction	 test	was	used	 to	assess	differences	 in	 the	mean	
effect	 of	 all	 parameters	 studied	 in	 each	group.	At	 this	 stage	of	
the	 analysis,	 groups	which	 showed	no	differentiation	 in	 regard	
to	the	characteristic	features	or	where	only	one	observation	was	
present	(e.g.	in	the	group	with	the	secretory	stage	endometrium	
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there	were	no	patients	with	cholelithiasis)	were	excluded	from	the	
study.	Statistical	calculations	were	performed	using	the	statistical	
package	R.
Results
Correlations	 between	 immunoexpression	 intensity	 of	
particular	antigens	and	clinical	features	of	the	patients	qualified	
for	the	study	(Table	I	and	II)	were	analyzed.			
All	 cases	 of	 ovarian	 clear	 cell	 carcinoma	 are	 treated	 as	
poorly	 differentiated	 (G-3).	 Therefore,	 only	 samples	 derived	
from	patients	with	 ovarian	 endometrioid	 adenocarcinoma	were	
subjected	 to	 grading	 analysis	 (Table	 III	 and	 IV).	No	 statistical	
differences	were	observed.
Ninety-six	 paraffin	 sections	 underwent	 the	 procedure	 of	
immunohistochemical	staining	to	detect	the	presence	of	the	MMP-
2	and	PTEN	protein	antigens.	A	positive	reaction	to	MMP-2	was	
achieved	in	92	sections.	No	reaction	to	MMP-2	was	observed	in	
1	 case	 of	 endometrial	 cyst,	 ovarian	 endometrial	 and	 clear	 cell	
carcinoma	 and	 proliferative	 endometrium.	 A	 positive	 reaction	
to	 PTEN	was	 achieved	 in	 93	 cases.	 No	 immunohistochemical	
reaction	was	noted	in	3	sections:	1	of	ovarian	endometrial	cancer,	
1	of	clear	cell	cancer	and	1	of	proliferative	endometrium.
After	 evaluating	 the	 MMP-2	 immunoreactivity	 according	
to	its	intensity,	the	lowest	values	were	found	in	the	proliferative	
endometrium,	 higher	 ones	 in	 the	 secretory	 endometrium,	
endometrial	 cysts,	 and	 ovarian	 endometrioid	 adenocarcinoma,	
and	the	highest	in	clear	cell	ovarian	carcinoma.	The	differences	
were	statistically	significant	(p<0.001)	(Table	V).
The	 immunohistochemical	 reaction	 to	 PTEN	 was	 the	
strongest	in	the	proliferative	endometrium	and	the	weakest	in	the	
secretory	endometrium	(Table	VI).	
Table I. Clinical characteristics of the patients. Part 1. 
Histopathological  
diagnosis
Age [years] BMI [kg/m2] Number of deliveries
mean median min max mean median min max mean median min max
Proliferative stage 41.3 42 31 53 23.3 22.3 18.6 33.2 1.4 1.5 0 3
Secretory stage 39.9 40 31 49 24.9 23.1 18.0 39.7 1.5 2 0 2
Endometrial cysts 36.1 37 22 55 22.8 22.1 17.0 32.8 0.9 0.5 0 3
Endometrioid 
adenocarcinoma
52.7 52.5 35 69 28.6 27.0 23.4 46.1 1.3 1.5 0 3
Clear cell 
adenocarcinoma
57.3 57 39 78 26.0 25.4 21.1 33.2 1.7 1.5 0 7
Table II. Clinical characteristics of the patients. Part 2.
Histopathological  
diagnosis
Deliveries Menopause Type II diabetes Hypothyroidism Cholelithiasis
no
(nulliparae)
yes
(multiparae)
no Yes no yes no yes no Yes
Proliferative stage 5 11 16 0 16 0 12 4 14 2
Secretory stage 1 12 12 0 13 0 12 1 13 0
Endometrial cysts 13 13 26 0 25 1 24 2 25 1
Endometrioid 
adenocarcinoma
6 14 8 11 19 1 18 2 19 1
Table III. Mean values of MMP-2 immunoexpression in ovarian endometrioid 
adenocarcinoma. 
Group
Grading
p
1 or 2 3
Endometrioid 
adenocarcinoma
1.07 1.73 0.202
Table IV. Mean values of PTEN protein immunoexpression in ovarian endometrioid 
adenocarcinoma. 
Group
Grading
p
1 or 2 3
Endometrioid 
adenocarcinoma
47.8 29.0 0.187
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Table V.  MMP-2 immunoexpression in tissue samples.
Group
MMP-2
Mean 95% CI p
Proliferative stage 0.68 0.53-0.87 ref.
ref.
Secretory phase 0.67 0.51-0.88 0.93
Endometrial cysts 0.86 0.71-1.05 0.14 0.072
Endometrioid adenocarcinoma 1.21 0.96-1.51 0.001 0.001
Clear cell adenocarcinoma 1.27 1.02-1.58 <0.001 <0.001
p<0.001
Table VI. PTEN protein immunoexpression in tissue samples. 
Group
PTEN
Mean 95% CI p
Proliferative stage 61.1 47.3-75.0 ref. 0.033
Secretory stage 37.8 23.0-52.7 0.033 ref.
Endometrial cysts 53.7 43.0-64.4 0.5 0.084
Endometrioid adenocarcinoma 43.8 31.5-56.1 0.1 0.49
Clear cell adenocarcinoma 50.2 38.2-62.1 0.32 0.18
p=0.17
Table VII. MMP-2 immunoexpression in the tissue samples in regard to BMI.  
Group
BMI [kg/m2]
p
[17-25] (25-46]
Proliferative stage 0.70 0.60 0.624
Secretory stage 0.76 0.57 0.286
Endometrial cysts 0.92 0.68 0.193
Endometrioid adenocarcinoma 1.61 1.05 0.076
Clear cell adenocarcinoma 1.31 1.15 0.568
Total interaction p=0.91 0.017
Table VIII. PTEN immunoexpression in regard to BMI.  
Group
BMI [kg/m2]
p
[17;25] (25;46]
Proliferative stage 63.2 53.1 0.648
Secretory stage 33.0 43.5 0.397
Endometrial cysts 53.4 54.6 0.939
Endometrioid adenocarcinoma 26.6 52.7 0.020
Clear cell adenocarcinoma 49.0 52.5 0.804
Total interaction p=0.367 0.152
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Due	to	the	fact	that	the	extreme	values	of	this	parameter	were	
reached	in	two	control	subgroups,	further	stages	of	the	statistical	
analysis	evaluating	PTEN	immunoreactivity	were	performed	by	
dividing	the	control	group	into	two	subgroups.	Next,	the	intensity	
of	 the	 immunohistochemical	 reaction	 was	 again	 compared,	
with	the	material	from	the	endometrium	of	the	proliferative	and	
secretory	 phase	 treated	 as	 one	 group.	As	 mentioned	 above	 in	
the	first	 case,	 the	difference	 in	 immunoexpression	between	 the	
proliferative	and	secretory	endometrium	was	distinct,	while	in	the	
subsequent	case	the	difference	was	observed	between	the	control	
group	and	the	material	from	endometrial	cysts	(p=0.084).
Significantly	 higher	 immunoreactivity	 of	 MMP-2	 was	
recorded	in	the	tissue	material	derived	from	the	group	of	patients	
up	 to	45	years	of	age.	PTEN	protein	 immunoreactivity	did	not	
correlate	with	patient	age	in	any	of	the	groups.
In	each	group,	MMP-2	immunoreactivity	values	were	found	
to	be	higher	in	women	whose	BMI	values	were	within	the	normal	
range	 (17-25	 kg/m2),	 however	 the	 differences	 between	 groups	
formed	 according	 to	 the	 BMI	were	 not	 statistically	 significant	
(Table	 VII).	 Only	 in	 the	 group	 of	 patients	 with	 endometrioid	
adenocarcinoma	of	the	ovary	and	proper	BMI	values,					MMP-
2	 immunoexpression	 indicated	 a	 strong	 growing	 tendency	 as	
compared	to	overweight	or	obese	patients	(p=0.076).
The	 PTEN	 protein	 was	 characterized	 by	 significantly	
different	 immunoreactivity	 in	 regard	 to	 BMI	 only	 in	 ovarian	
endometrial	cancer	(Table	VIII).	PTEN	immunoexpression	was	
considerably	 higher	 in	 overweight	 and	 obese	 patients	 than	 in	
patients	without	similar	metabolic	disorders	(p=0.02).	
Analysis	 of	 the	 influence	 of	 parity	 on	MMP-2	 and	 PTEN	
immunoreactivity	did	not	reveal	any	relationship.								
The	evaluation	of	MMP-2	immunoreactivity	in	the	samples	
from	 endometrioid	 adenocarcinoma	 related	 to	 the	 menopause	
effect	 on	 intensity	 of	 immunohistochemical	 reaction	 did	 not	
indicate	statistically	significant	correlations.	In	the	material	from	
patients	 with	 clear	 cell	 cancer	 after	 menopause,	 considerably	
weaker	MMP-2	 immunoexpression	was	 observed	 as	 compared	
to	 the	 results	 of	 women	 before	 menopause,	 nonetheless	 the	
differences	were	not	significant.	PTEN	immunoreactivity	did	not	
correlate	with	menopause.	
A	detailed	analysis	of	MMP-2	and	PTEN	immunoreactivity	
did	 not	 prove	 any	 relationship	 between	 the	 immunoexpression	
of	 the	 examined	 antigens	 in	 the	 study	 and	 the	 control	 groups.	
(Figure	1).
Discussion
Neoplastic	transformation	of	ectopic	endometrial	foci	seems	
to	affect	1%	of	cases	(14,16,25-27).
Melin	et	al.,	using	the	data	from	the	National	Swedish	Cancer	
Registry,	studied	the	incidence	rate	of	ovarian	cancer	and	other	
malignancies	 among	 patients	 with	 endometriosis	 hospitalized	
between	 1969-2000	 (28).	 The	 index	 of	 risk	 for	 developing	
malignancies	 generally	 equaled	 that	 for	 the	 entire	 population	
and	 was	 1.04,	 whereas	 it	 was	 considerably	 higher	 for	 ovarian	
adenocarcinoma	 (1.43),	 and	 even	 reached	 2.23	 among	women	
with	persisting	endometriosis.	
Up	to	10%	of	endometrial	ovarian	cancer	cases	arise	from	
ectopic	 endometrial	 foci,	 the	 remaining	 90%	 derive	 from	 the	
epithelium	 primarily	 covering	 the	 ovary.	 Association	 of	 clear	
cell	 cancer	 with	 endometriosis	 is	 stronger	 and	 concerns	 about	
35%	 of	 cases	 [29].	 In	 20-25%	 of	 clear	 cell	 adenocarcinoma	
cases,	a	component	of	endometrioid	adenocarcinoma	is	observed	
histopathologically,	 providing	 indirect	 evidence	 for	 a	 mutual	
origin	of	these	two	neoplasms.
In	 3	 of	 20	 cases	 of	 ovarian	 endometrioid	 adenocarcinoma	
in	 our	 study,	 the	 presence	 of	 texture	 signifying	 neoplastic	
transformation	 on	 the	 basis	 of	 the	 previous	 endometrial	 focus	
(15%)	was	microscopically	detected.	Tissue	material	from	clear	
cell	carcinoma	of	21	women	revealed	concomitant	endometrioid	
adenocarcinoma	in	4.8%	cases.	
Wu	 et	 al.,	 confirmed	 a	 monoclonal	 character	 of	 the	 cells	
in	 75%	 of	 endometrial	 cyst	 cases	 simultaneous	 with	 ovarian	
endometrioid	 adenocarcinoma	 foci,	 and	 in	 28%	 of	 cyst	 cases	
without	 cancer	 foci	 [30].	 This	 information	 indirectly	 presents	
the	 evidence	 of	 changes	 undergoing	 in	 the	 endometrial	 cells,	
which	in	effect	enable	cellular	transformation	and	proliferation.	 
There	are	regions	1p,	5q	(25%),	6p,	6q	(27%),	9p	(21%),	10q,	11q,	
22q	(15-31%)	among	DNA	fragments,	common	for	endometrial	
and	malignant	cells,	which	most	often	get	damaged	[14,	15,	29,	
31-33].	 Loss	 of	 heterozygoticity	 with	 the	 10q	 localization	 is	
associated	with	inactivity	of	the	PTEN	suppressor	gene.
Obata	et	al.,	were	among	the	first	who	proved	the	incidence	
of	 LOH	 and	 somatic	 mutations	 of	 the	 PTEN	 gene,	 both	 in	
endometrial	 cysts	 and	 foci	 of	 concomitant	 cancer	 [31].	 The	
authors	 suspect	 that	 lack	of	heterozygoticity	 signifies	 an	 initial	
phase	of	cellular	independence,	while	the	occurrence	of	the	PTEN	
gene	somatic	mutation	is	a	trigger	element	for	carcinogenesis.				
Similarity	 between	 the	 structure	 of	 the	 PTEN	 protein	 and	
tensin	 inspired	Tamura	 et	 al.,	 to	 search	 for	 an	 interaction	with	
extracellular	matrix	(ECM)	elements	[34].	There	is	evidence	that	
the	mechanisms	of	cell	survival	and	apoptosis	are	dependent	not	
only	upon	 intracellular	proteins	but	 also	upon	 the	 contact	with	
extracellular	elements	[29].
Goffin	et	al.,	investigated	metalloproteinase	expression	in	the	
human	endometrium	during	the	entire	menstrual	cycle	[35].	They	
observed	that	some	protenases	from	the	family	exhibit	expression	
during	the	entire	menstrual	cycle	(MMP-2,	MMP-19,	MT-MMP-1,	
 
Figure 1. MMP-2 and PTEN immunoexpression.  
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MT-MMP-2).	The	other	group	is	synthesized	only	at	the	time	of	
menstruation	(MMP-1,	MMP-3,	MMP-8,	MMP-9,	MMP-12).	The	
maintenance	of	the	matrix	metalloproteinase	production	during	the	
entire	menstrual	cycle	may	provide	evidence	for	the	involvement	
of	these	endopeptidases	in	the	proper	course	of	endometrial	cell	
metabolism.	We	 detected	 immunohistochemically	 the	 presence	
of	 MMP-2	 both	 in	 the	 proliferative	 and	 secretory	 stages	 of	
the	 physiological	 endometrium.	 MMP-2	 immunoexpression	
appeared	to	be	significantly	higher	in	the	endometrial	secretory	
stage	as	compared	to	the	proliferative	stage	(p<0.001).	
Gaetje	 et	 al.,	 observed	 an	 evidently	 increased	 production	
of	 the	 membrane-type	MT-MMP-5	 in	 the	 cells	 of	 the	 ectopic	
endometrium,	 which	 they	 believed	 to	 be	 the	 reason	 for	 the	
increased	 ability	 of	 these	 cells	 to	 adhere	 and	 invade	 other	
cells	 [12].	MT-MMP-5	 is	 a	well	 known	 activator	 of	 numerous	
metalloproteinases,	including	MMP-2.	
We	 evaluated	 MMP-2	 immunoreactivity	 not	 only	 in	 the	
physiological	 epithelium	 of	 the	 proliferative	 (n1=16)	 and	
secretory	(n2=13)	endometrium,	but	also	in	endometrial	cysts	of	
the	ovary	(N1=26).	It	differed	significantly	in	intensity	among	the	
groups	and	was	the	strongest	(p<0.001)	in	endometrial	cysts.	The	
results	demonstrate	the	MMP-2	involvement	in	the	pathogenesis	
of	forming	ectopic	endometrial	foci.	
Ovarian	cancers	are	characterized	by	a	special	proliferation	
process	 in	 which	 the	 moment	 of	 malignant	 cell	 penetration	
to	 the	 peritoneal	 cavity	 is	 a	 key	 element	 in	 the	 prognosis.	We	
know	 that	 secondary	 ovarian	 carcinomas	 do	 not	 disseminate	
intraperitoneally	 in	 a	 similar	 way,	 thus	 we	 would	 like	 to	
understand	which	properties	of	the	cells	determine	such	course.	
One	 of	 the	 theories	 considers	 its	 higher	 capacity	 to	 synthesize	
metalloproteinases	[36].
Davidson	and	Schmalfeldt	evaluated	 the	activity	of	MMP-
2,	MMP-9	 and	 their	 tissue	 activators	 [37,	 38].	 They	 observed	
that	 MMP-2	 and	 MMP-9	 capacity	 for	 invasion	 grew	 along	
with	the	increase	in	their	expression	in	cancerous	cells,	without	
considering	histopathological	grading	of	the	cancer.	
According	to	Sillanpää,	however,	an	increase	in	MMP-2	and	
MMP-9	tissue	expression	is	accompanied	by	a	better	prognosis	
and	 longer	 survival	 rates	 (p<0.0057)	 [39].	 In	 our	 analysis	 the	
relationship	 between	 MMP-2	 antigen	 immunoexpression,	
microscopic	 diagnosis	 and	 clinical	 features	 was	 investigated.	
MMP-2	 immunoreactivity	 differed	 significantly	 between	 the	
study	groups	and	controls	(p<0.001).	A	higher	MMP-2	expression	
in	successive	groups	may	imply	a	growing	invasive	potential	of	
the	epithelial	cells	in	endometrial	cysts,	endometrioid	and	clear	
cell	adenocarcinoma	(Table	VII).	
In	 the	 present	 study,	 MMP-2	 immunoexpression	 was	
significantly	 higher	 (p<0.05)	 in	 the	 group	of	women	below	46	
years	of	age	than	in	older	patients.	This	correlation	was	strongly	
expressed	in	women	with	diagnosed	ovarian	endometriosis	and	
endometrioid	ovarian	cancer.	The	immunoreaction	to	MMP-2	in	
the	tissue	samples	collected	from	the	older	patients,	irrespective	
of	 primary	 histopathological	 diagnosis,	 displayed	 a	 weaker	
intensity.					
Kenny	 et	 al.,	 are	 of	 the	 opinion	 that	 the	 interaction	 of	
potentially	 malignant	 or	 malignant	 cells	 with	 such	 a	 specific	
environment	as	the	mesothelium	covering	the	abdominal	cavity	
is	the	key	to	understand	ovarian	cancer	proliferation	process	[36].	
The	authors	observed	that	the	process	of	adhesion	and	invasion	
was	 accompanied	 by	 intensified	 MMP-2	 expression	 in	 the	
cancerous	as	well	as	mesothelial	cells.	
A	 hypothetical	 effect	 of	 PTEN	 activity	 loss	 on	 the	
pathogenesis	 of	 endometriosis,	 endometrioid	 and	 clear	 cell	
ovarian	cancer,	as	well	as	metalloproteinase	involvement	in	the	
early	stage	of	adhesion	and	proliferation	of	ectopic	endometrial	
foci,	encouraged	us	to	interpret	these	phenomena	together.
Tumor	 suppressor	 properties	 of	 PTEN	 are	 relatively	well-
known	 [8].	 However,	 the	 relationship	 of	 PTEN	 expression	
and	 cellular	 activity	 with	 cell	 invasiveness	 remains	 obscure.	
The	 connection	 of	 PTEN	 and	 metalloproteinase	 activity	 with	
pathogenesis	 of	 endometriosis	 and	 neoplastic	 transformation	
requires	 extensive	 investigation.	 Koul	 et	 al.,	 carried	 out	
crucial	 studies	 to	 understand	 the	 role	 of	 PTEN	 in	 regulation	
of	metalloproteinase	 activity	 [6].	They	 reported	 that	 cells	with	
active	 PTEN/MMAC1	 were	 characterized	 by	 limited	 growth	
and	 significantly	 more	 frequent	 apoptosis	 via	 anoikiosis	 (the	
process	of	programmed	cell	death	 that	 starts	with	degeneration	
of	the	nucleus).	Moreover,	properly	functioning	PTEN	showed	a	
three-fold	decrease	in	cell	migration	and	invasion	capacity.	These	
authors	indicated	that	PTEN	correlates	not	only	with	pro-MMP-2	
inactivation	but	also	directly	inhibits	expression	and	transcription	
of	genes	responsible	for	MMP-2	synthesis.	
Relative	 availability	 of	 immunohistochemical	 methods	
was	 the	 reason	 why	 they	 were	 selected	 for	 our	 research.	 The	
analysis	 of	 immunoreactivity	 of	 the	 preferred	 antigens	 is	 a	
method	enabling	the	evaluation	of	the	final	product	of	frequently	
complex	multistage	pathways.	Taking	into	account	endometriosis	
incidence	 and	 its	 potential	 of	 neoplastic	 transformation,	 we	
decided	 to	 seek	 the	marker	of	 increased	 risk	of	cancerogenesis	
based	on	ectopic	endometrium.	We	made	an	attempt	to	assess	the	
importance	of	PTEN	and	MMP-2	activity	in	the	pathogenesis	of	
endometriosis,	endometrial	and	clear	cell	ovarian	carcinoma.	
PTEN	 is	 a	 potential	 regulator	 of	 MMP-2	 activity,	 acting	
on	 different	 levels.	 Its	 inactivation	 might	 be	 a	 trigger	 factor	
for	 neoplastic	 proliferation	 induced	 on	 the	 basis	 of	 ectopic	
endometrium.	
The	PTEN	protein	 immunoexpression	 in	 the	 endometrium	
depended	on	the	stage	of	the	menstrual	cycle.	A	stronger	PTEN	
antigen	 immunoreactivity	 was	 observed	 in	 the	 proliferative	
rather	than	in	the	secretory	stage.	The	difference	was	statistically	
significant	 (<0.05).	 This	 condition	 might	 reflect	 an	 enhanced	
activity	 of	 suppressive	 PTEN	 in	 the	 intensive	 physiological	
stage	of	cell	proliferation.	PTEN	immunoreactivity	reached	the	
lowest	value	in	the	secretory	endometrium,	at	the	stage	of	cellular	
stability	and	was	in	compliance	with	the	observations	of		Mutter	
and	Guzelgloglu-Kayisli	[40,	41].
Loss	 of	 the	 PTEN	 gene	 activity	 is	 a	 characteristic	
phenomenon	of	an	early	stage	of	ovarian	carcenogenesis	induced	
on	the	basis	of	ectopic	endometrial	foci	[14,	15,	24,	29,	31-33].	
In	 our	 study,	 the	 analysis	 showed	 the	 highest	 PTEN	
immunoexpression	 in	 endometrial	 cysts,	 followed	 by	 a	 lower	
immunoexpression	in	the	clear	cell	adenocarcinoma	cells,	and	the	
lowest	in	ovarian	endometrioid	adenocarcinoma.	The	differences	
in	 immunoreactivity	 between	 the	 groups	 were	 not	 statistically	
significant	although,	in	compliance	with	findings	of	other	authors,	
they	 may	 correspond	 to	 a	 more	 frequent	 incidence	 of	 PTEN	
gene	 dysfunction	 in	 ovarian	 endometrioid	 adenocarcinomas	 as	
compared	to	clear	cell	adenocarcinomas	of	the	ovary	[32,	42].
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Similarly	to	Kazandi,	Kolasy,	and	Gomes,	we	did	not	observe	
any	differences	in	PTEN	immunoreactivity	in	relation	to	grading	
of	the	endometrioid	adenocarcinoma	[32,	42,	43].
The	 body	 mass	 index	 was	 an	 additional	 clinical	 feature	
considered	 in	 our	 study.	 In	 patients	with	 ovarian	 endometrioid	
adenocarcinoma,	 both	 PTEN	 and	 MMP-2	 immunoreactivity	
clearly	 depended	 on	 the	 BMI	 values.	 PTEN	 antigen	
immunoexpression	 was	 significantly	 higher	 in	 obese	 women	
(p=0.02),	 while	 MMP-2	 immunoexpression	 was	 lower	 in	 that	
group	 (statistically	 not	 significant).	 Considering	 the	 properties	
of	PTEN	in	the	regulation	of	cellular	response	to	IGF-1	activity,	
it	 can	 be	 supposed	 that	 the	 PTEN	 protein	 reduces	 MMP-2	
expression	in	women	suffering	from	ovarian	cancer	with	probable	
insulin	resistance.
Conclusions
The	main	aim	of	the	present	study	was	to	detect	the	marker	
of	an	 increased	 risk	of	neoplastic	 transformation	deriving	 from	
ectopic	endometrium.	We	did	not	find	any	relationship	between	
PTEN	immunoreactivity	and	MMP-2	immunoexpression	among	
the	examined	patients.	According	to	the	results	mentioned	above,	
simultaneous	 determination	 of	 PTEN	 and	 metalloproteinase-2	
immunoexpression	 in	 ectopic	 endometrial	 foci	 in	 patients	with	
endometriosis	 cannot	be	used	 to	 identify	women	with	a	higher	
risk	of	neoplastic	transformation.
To	the	best	of	our	knowledge,	our	research	is	the	first	complex	
study	on	the	importance	of	the	PTEN	protein	and	MMP-2	in	the	
pathogenesis	of	endometriosis	and	ovarian	cancer.				
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